DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Pharmacological Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library is a rigorously curated set of 2,320 bioactive compounds approved or recognized by major regulatory agencies including the FDA, EMA, HMA, CFDA, and PMDA (APExBIO). Each compound is provided as a 10 mM DMSO solution, quality-controlled for stability up to 24 months at -80°C. The library supports high-throughput (HTS) and high-content screening (HCS) workflows for drug repositioning and pharmacological target identification (Khamrui et al., 2024). Applications span oncology, neurodegeneration, and rare metabolic disorders. The format enables consistent integration with automated platforms and minimizes experimental variability. Representative compounds include doxorubicin, metformin, and atorvastatin, each with well-characterized mechanisms of action.

Biological Rationale

Clinically approved drugs possess documented pharmacokinetic, safety, and efficacy profiles, making them prime candidates for drug repositioning. High-throughput screening of these compounds accelerates the identification of new therapeutic applications and targets (related article). The DiscoveryProbe™ FDA-approved Drug Library uniquely compiles compounds with diverse mechanisms—agonists, antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators—enabling broad interrogation of cellular pathways. This approach supports the rapid validation of novel targets, as seen in enzyme inhibition studies and pathway modulation assays (Khamrui et al., 2024).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library encompasses compounds targeting a wide range of molecular mechanisms. For example:

• Receptor agonists/antagonists: Modulate G protein-coupled receptors, nuclear receptors, and ion channels.
• Enzyme inhibitors: Target kinases, proteases, and metabolic enzymes such as succinyl-CoA:glutarate-CoA transferase (SUGCT) (Khamrui et al., 2024).
• Ion channel modulators: Alter membrane potential, influencing cell signaling and excitability.
• Signal pathway regulators: Affect downstream transcriptional and metabolic networks.

Representative compounds like doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor) exemplify this diversity.

Evidence & Benchmarks

• The APExBIO DiscoveryProbe™ FDA-approved Drug Library enabled high-throughput identification of valsartan and losartan carboxylic acid as SUGCT enzyme inhibitors in cell-based assays (Khamrui et al., 2024, DOI).
• All 2,320 compounds are pre-dissolved at 10 mM in DMSO, supporting reproducible screening in 96-well and deep-well formats (product page).
• Validated for stability: 12 months at -20°C and 24 months at -80°C, minimizing compound degradation (product page).
• Facilitates rapid drug repositioning in cancer research, as highlighted in related drug library reviews (related article).
• Supports screening for modulators of rare disease pathways, such as glutaric aciduria type 1 and 3, by enabling enzyme inhibition profiling (Khamrui et al., 2024, DOI).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for multiple screening paradigms:

• Drug repositioning screening: Enables identification of new indications for existing drugs.
• Pharmacological target identification: Supports discovery of novel drug–target interactions.
• Cancer research drug screening: Facilitates selection of cytotoxic and targeted agents for oncology models.
• Neurodegenerative disease drug discovery: Streamlines identification of neuroactive compounds.
• Signal pathway regulation studies: Allows systematic perturbation of key cellular pathways.

Related resources, such as this comparative review, emphasize the library’s ready-to-screen, quality-controlled format; this article extends those findings by detailing integration parameters and specific mechanistic case studies.

Common Pitfalls or Misconceptions

• The library is not a substitute for primary screening of uncharacterized chemical matter; it is limited to compounds with existing regulatory or pharmacopeial recognition.
• Not all compounds are active in every cell type or assay format; results may differ based on expression of targets or metabolic context.
• False positives can arise from DMSO-sensitive assays or compound aggregation; appropriate controls are required.
• It does not include investigational or preclinical-only compounds; only clinically approved or listed agents are present.
• Compound concentrations are standardized to 10 mM in DMSO, but working dilutions must be empirically validated for each assay system.

Workflow Integration & Parameters

The library is designed for seamless integration into automated high-throughput and high-content screening pipelines. Key parameters include:

• Format flexibility: Available in 96-well plates, deep-well blocks, or 2D barcoded screw-top tubes.
• Compound stability: Maintained for 12 months at -20°C, 24 months at -80°C; shipped on blue ice for evaluation samples and optionally for larger orders.
• Solvent compatibility: All compounds are pre-dissolved in DMSO, compatible with standard cell-based and biochemical assays.
• Storage tracking: 2D barcoding supports LIMS integration and traceability.

Operational protocols are described in-depth on the product page and in troubleshooting guides. For workflow-specific performance metrics and troubleshooting, see this resource, which this article updates by including stability and storage considerations.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO provides an unparalleled resource for high-throughput and high-content screening, drug repositioning, and pharmacological target identification. Its regulatory pedigree, format flexibility, and quality control enable reproducible, scalable research across cancer, neurodegenerative, and rare disease domains. Continued integration with advanced screening platforms and expansion with new regulatory approvals will further enhance its translational utility (Khamrui et al., 2024).